METHOD OF TREATMENT WITH BRAF INHIBITOR

The disclosure is directed to a method of treating humans suffering from V600 mutant melanoma that incorporates the detection of the presence or absence of at least one mutation in at least one NRAS protein and/or at least one MEK1 protein, or a gene encoding said protein, and subsequently initiatin...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	GILMER, TONA, M, BLEAM, MAUREEN, GREGER, JAMES, G., JR, LIU, LI, LAQUERRE, SYLVIE, G
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES ENZYMOLOGY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PHYSICS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROCESSES OF PREPARING SUCH COMPOSITIONS SPIRITS TESTING VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The disclosure is directed to a method of treating humans suffering from V600 mutant melanoma that incorporates the detection of the presence or absence of at least one mutation in at least one NRAS protein and/or at least one MEK1 protein, or a gene encoding said protein, and subsequently initiating treatment, modifying treatment, or discontinuing treatment with a chemotherapeutic agent selected from a BRaf inhibitor or other suitable agent based upon the presence or absence of said mutation. La présente invention concerne une méthode de traitement de patients atteints d'un mélanome V600 mutant qui consiste à détecter la présence ou l'absence d'au moins une mutation dans au moins une protéine NRAS et/ou au moins une protéine MEK1, ou d'un gène codant pour ladite protéine, et par la suite à initier le traitement, modifier le traitement, ou arrêter le traitement par un agent chimiothérapique choisi parmi un inhibiteur de la Braf ou un autre agent approprié en se basant sur la présence ou l'absence de ladite mutation.